Mangoceuticals Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $315.2K-48.8% YoYTTM through 30 Jun 2026
Net Income -$15.1MTTM through 30 Jun 2026
Free Cash Flow -$3.9MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 42.7% |
| Operating Margin | -4,606.8% |
| Net Margin | -4,791.3% |
Returns
-25.3%ROE
-106.6%ROA
Balance Sheet Health
Debt / Equity0.02x
Current Ratio0.29x
Net Debt-$174.6Knet cash position
Cash & Equivalents$228.7K
Quality Metrics
Altman Z-Score-3.98
Piotroski F-Score1 / 9
FCF Margin-1,234.3%
Multi-Year Trend
RevenueFY2025: $456K
Diluted EPS-$1.00TTMFY2025: $-2.05
Dividend
No dividend
Segment Performance
No segment data available.
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.